Publicações

Patient (Pt) Preference for the Pertuzumab-Trastuzumab Fixed-Dose Combination for Subcutaneous Use (Ph Fdc Sc) in Her2-Positive Early Breast Cancer (Ebc): Primary Analysis of the Open-Label, Randomised Crossover Phrancesca Study

AuthID
P-00S-WHK

Author(s)

O'Shaughnessy, J

Sousa, S

Cruz, J

Fallowfield, L

Auvinen, P

Pulido, C

Cvetanovic, A

Wilks, S

Ribeiro, L

Burotto, M

Klingbiel, D

Messeri, D

Alexandrou, A

Trask, P

Fredriksson, J

Machackova, Z

Stamatovic, L

Tipo de Documento

Abstract

Year published

2020

Publicado

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 31, Páginas: S306-S307 (2)

Conference

Esmo Virtual Congress, Date: SEP 19-OCT 18, 2020, Location: ELECTR NETWORK, Patrocinadores: European Soc Med Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1016/j.annonc.2020.08.287

Wos: WOS:000573469100165

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Patient (Pt) Preference for the Pertuzumab-Trastuzumab Fixed-Dose Combination for Subcutaneous Use (Ph Fdc Sc) in Her2-Positive Early Breast Cancer (Ebc): Primary Analysis of the Open-Label, Randomised Crossover Phrancesca Study

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Patient (Pt) Preference for the Pertuzumab-Trastuzumab Fixed-Dose Combination for Subcutaneous Use (Ph Fdc Sc) in Her2-Positive Early Breast Cancer (Ebc): Primary Analysis of the Open-Label, Randomised Crossover Phrancesca Study

Links Úteis

Ajuda